DK3972643T3 - Komplementsystemantagonister til anvendelse i fremgangsmåder til behandling af paraproteinemiske neuropatier - Google Patents

Komplementsystemantagonister til anvendelse i fremgangsmåder til behandling af paraproteinemiske neuropatier

Info

Publication number
DK3972643T3
DK3972643T3 DK20729653.4T DK20729653T DK3972643T3 DK 3972643 T3 DK3972643 T3 DK 3972643T3 DK 20729653 T DK20729653 T DK 20729653T DK 3972643 T3 DK3972643 T3 DK 3972643T3
Authority
DK
Denmark
Prior art keywords
paraproteinemic
neuropathies
treating
methods
complement system
Prior art date
Application number
DK20729653.4T
Other languages
English (en)
Inventor
Christophe Blanchetot
Kevin Budding
Erik Hack
Karen Silence
De Walle Inge Van
Der Pol Ludo Van
Péter Boross
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Application granted granted Critical
Publication of DK3972643T3 publication Critical patent/DK3972643T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20729653.4T 2019-05-21 2020-05-21 Komplementsystemantagonister til anvendelse i fremgangsmåder til behandling af paraproteinemiske neuropatier DK3972643T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1907153.9A GB2584105B (en) 2019-05-21 2019-05-21 Methods of treating neuropathy
PCT/EP2020/064234 WO2020234432A1 (en) 2019-05-21 2020-05-21 Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies

Publications (1)

Publication Number Publication Date
DK3972643T3 true DK3972643T3 (da) 2025-07-21

Family

ID=67385155

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20729653.4T DK3972643T3 (da) 2019-05-21 2020-05-21 Komplementsystemantagonister til anvendelse i fremgangsmåder til behandling af paraproteinemiske neuropatier

Country Status (21)

Country Link
EP (2) EP4570316A3 (da)
JP (3) JP7607590B2 (da)
KR (1) KR20220010505A (da)
CN (2) CN114269382B (da)
AU (2) AU2020279543B2 (da)
BR (1) BR112021023198A2 (da)
CA (1) CA3138401A1 (da)
DK (1) DK3972643T3 (da)
EA (1) EA202193189A1 (da)
ES (1) ES3035736T3 (da)
FI (1) FI3972643T3 (da)
GB (1) GB2584105B (da)
HU (1) HUE072743T2 (da)
IL (1) IL288010A (da)
LT (1) LT3972643T (da)
MA (1) MA71752A (da)
MX (2) MX2021014170A (da)
PL (1) PL3972643T3 (da)
PT (1) PT3972643T (da)
SG (1) SG11202112232YA (da)
WO (1) WO2020234432A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
CN117597353A (zh) * 2021-03-18 2024-02-23 艾菲洛之克公司 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途
EP4308591A4 (en) * 2021-03-18 2025-04-02 Affilogic POLYPEPTIDES FOR COMPLEMENT INHIBITION
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
US20240166692A1 (en) * 2021-03-18 2024-05-23 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
MX2024008273A (es) * 2021-12-30 2024-07-19 Annexon Inc Composiciones y metodos para el tratamiento de la enfermedad de huntington.
MA71448A (fr) * 2022-07-14 2025-04-30 argenx BV Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm)
EP4676952A2 (en) * 2023-03-07 2026-01-14 The Cleveland Clinic Foundation Human complement component 2 binding molecules
WO2025146509A1 (en) * 2024-01-05 2025-07-10 argenx BV Methods of treating multifocal motor neuropathy (mmn)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2008030505A2 (en) * 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
LT3028716T (lt) * 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
PL2753636T3 (pl) * 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
CN102949719A (zh) * 2012-04-28 2013-03-06 上海市徐汇区中心医院 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
EP2997045A4 (en) * 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
US9944717B2 (en) 2013-05-23 2018-04-17 Broteio Pharma B.V. Binding molecules that bind human complement factor C2 and uses thereof
WO2015089368A2 (en) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
CN108026134A (zh) * 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
WO2017196960A1 (en) * 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
SG11201907583TA (en) * 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
CA3078971A1 (en) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
PL3893924T3 (pl) * 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania

Also Published As

Publication number Publication date
CN118021970A (zh) 2024-05-14
PL3972643T3 (pl) 2025-09-08
JP2022533705A (ja) 2022-07-25
CN114269382B (zh) 2024-02-23
AU2026205212A1 (en) 2026-07-23
EP4570316A3 (en) 2025-08-13
MX2021014170A (es) 2022-01-04
PT3972643T (pt) 2025-07-15
NZ781789A (en) 2025-03-28
EP4570316A2 (en) 2025-06-18
LT3972643T (lt) 2025-07-10
JP7607590B2 (ja) 2024-12-27
EP3972643A1 (en) 2022-03-30
JP2025041724A (ja) 2025-03-26
ES3035736T3 (en) 2025-09-08
AU2020279543B2 (en) 2026-06-04
HUE072743T2 (hu) 2025-12-28
GB2584105A (en) 2020-11-25
GB201907153D0 (en) 2019-07-03
KR20220010505A (ko) 2022-01-25
AU2020279543A1 (en) 2021-11-25
WO2020234432A1 (en) 2020-11-26
CN114269382A (zh) 2022-04-01
MA71752A (fr) 2025-05-30
JP2025038109A (ja) 2025-03-18
EA202193189A1 (ru) 2022-03-11
CA3138401A1 (en) 2020-11-26
SG11202112232YA (en) 2021-12-30
IL288010A (en) 2022-01-01
US20250066460A1 (en) 2025-02-27
EP3972643B1 (en) 2025-05-14
BR112021023198A2 (pt) 2022-01-04
FI3972643T3 (fi) 2025-07-16
MX2025014486A (es) 2026-01-07
GB2584105B (en) 2023-08-02

Similar Documents

Publication Publication Date Title
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
DK3902547T3 (da) Csf1r-hæmmere til anvendelse i cancerbehandling
DK4028010T3 (da) Vs-6063 i kombination med ch5126766 til behandlingen af kræft
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3435996T3 (da) Elafibranor til anvendelse i behandlingen af primær biliær cholangitis
EP3307713A4 (en) EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
IL288010A (en) Antagonists to the complement system for the treatment of paraproteinemic neuropathies
DK3448426T3 (da) Fremgangsmåder til behandling af patienter med familiær hyperkolesterolæmi
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
EP3402486C0 (en) CCX168 FOR USE IN THE TREATMENT OF C3 GLOMERULOPATHY
EP3277276A4 (en) Methods of administering glutaminase inhibitors
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK4034122T3 (da) Fremgangsmåder til behandling af hyperfenylalaninæmi
IL290348A (en) Surface treatment compositions and methods
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
DK3395359T3 (da) Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
DK3717011T3 (da) Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
IL272092A (en) Methods of treating behavior alterations
DK3236983T3 (da) Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet
EP3532063A4 (en) POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION
IL282041A (en) Egfr inhibitors for treating keratodermas
DK3742950T3 (da) Apparat til behandling af gulve